Somnomed Limited (ASX:SOM)

$2.08

right-arrow Created with Sketch. 0 (0%)
MCAP $172.1M
Last trade 15.59pm 18/01/2022 20mins delayed

Latest Announcements

10/12/2021SOMSomnomed Limited
01/12/2021SOMSomnomed Limited
25/11/2021SOMSomnomed Limited
235
MCap
25/11/2021SOMSomnomed Limited
271
MCap
09/11/2021SOMSomnomed Limited
04/11/2021SOMSomnomed Limited
28/10/2021SOMSomnomed Limited
115
MCap
28/10/2021SOMSomnomed Limited

Company Overview

SomnoMed Limited (SomnoMed) is an Australia-based company, which is engaged in the commercialization of the SomnoDent MAS and other oral devices for sleep related disorders in Australia and overseas. The Company provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. SomnoMed has developed the SomnoDent, a collection of oral devices. SomnoDent includes two product line, such as signature line and standard line. Its signature line products include Herbst Advance Elite, Fusion, Flex and Classic, and standard line products include Herbst Advance, Air/Air+, Morning Repositioner and Alpha. SomnoMed has developed the SomnoBrux, a custom fit acrylic occlusal splint. SomnoBrux product includes Michigan. SomnoMed has developed the SomGauge, is an autoclavable instrument, which can be used to construct accurate and reliable bite records.

SOM in the news

SomnoMed (SOM) has appointed four new Directors and current CEO Neil Verdal-Austin…
SomnoMed (SOM), a company working in diagnostics and treatment for sleep disorders…

Search Previous Announcements